News

American Association for Cancer Research (AACR) 2019 – STRO-002 Poster

April 11, 2019

American Association for Cancer Research (AACR) 2019

A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-002, An Anti-Folate Alpha (FolRα) Antibody Drug Conjugate, In Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube Or Primary Peritoneal Cancers) And Endometrial Cancers. NCT03748186